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Abstract: The renin-angiotensin system (RAS) is known mainly as a regulator of cardiovascular homeostasis. 
However, it has also been shown to mediate processes such as proliferation, apoptosis, angiogenesis, and car-
cinogenesis. Nonmelanoma skin cancers (NMSC) — including basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) — are among the most common cancers. The aim of the present study was to determine the 
immunohistochemical expression of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 
2 (ACE2), and Ki-67 antigen in archival samples of normal skin, actinic keratosis, and malignant skin lesions. 
Cytoplasmic-nuclear ACE immunoreactivity was observed in 99% of examined cases of both normal skin and 
cancers. Significantly higher ACE immunoreactivity occurred in normal skin, as compared with BCC and SCC 
(p < 0.01, p < 0.0001, respectively). Additionally, ACE immunoreactivity was also significantly higher in BCC, 
compared with SCC (p < 0.05). ACE2 immunoreactivity was noted in basal epidermal layers and in sebaceous 
gland cells in normal skin, though not in NMSC. These novel observations suggest that ACE and skin RAS 
may be involved in the pathogenesis of malignant skin lesions. (Folia Histochemica et Cytobiologica 2013, Vol. 
51, No. 3, 232–238)
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Introduction
The renin-angiotensin system (RAS) consists of 
systemic and local parts. The systemic RAS has been 
mainly perceived as an important regulator of car-
diovascular homeostasis and as a key factor in the 
pathogenesis of hypertension and atherosclerosis. The 
local renin-angiotensin systems observed in various 
organs act mainly over a limited area [1]. The first 
element of RAS is liver-derived angiotensinogen, 
a glycoprotein cleaved by renin to generate decapepti-
de angiotensin I (Ang I) [1]. The angiotensin-conver-
ting enzyme (ACE) is a protease capable of cleaving 
the inactive Ang I to active octapeptide angiotensin 
II (Ang II), which is regarded as the most active re-
gulator of the systemic RAS [1]. The actions of Ang 
II are mediated predominantly through its specific 
receptors, Ang II receptor type 1 (AT1R) and Ang II 
receptor type 2 (AT2R) [2]. Most of the known effects 
of Ang II — such as its stimulation of angiogenesis, 
cellular proliferation, inflammatory and antiapoptotic 
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responses — occur via AT1R [3, 4]. AT2R-mediated 
actions have been shown to oppose those elicited 
by AT1R [5, 6]. However, several lines of evidence 
suggest that signaling via AT2R may also be proan-
giogenic and proinflammatory [7]. Although Ang II is 
the most important effector of the RAS, there are also 
other products of aminopeptidase activity of ACE and 
ACE2, such as angiotensin III (Ang III), angiotensin 
IV (Ang IV), and angiotensin-(1-7) [(Ang-(1-7)], 
which all show potent biological activity [9–12]. Ang-
(1-7) is an endogenous 7-amino-acid peptide hormone 
that exerts antiproliferative activity and counteracts 
the vasodilative and apoptotic properties of Ang II 
[13]. The specific effects of Ang-(1-7) are mediated 
by a recently identified receptor, the mas oncogene 
product (MAS) [14]. Ang-(1-7) may be formed from 
Ang I through cleavage of angiotensin-(1-9), or it may 
be generated directly from Ang II by the enzymatic 
activity of ACE2 [15]. ACE2, discovered almost 
a decade ago, is an ACE homologue and a zinc-me-
tallopeptidase [15]. It has been suggested that ACE2 
may oppose the effects of ACE on the organ and 
tissue levels through the generation of Ang-(1-7) by 
the local RAS [15]. The local RAS systems have been 
detected in various species and in diverse organs, such 
as the brain, the testes, the prostate, the pancreas, 
the adrenal gland, and the mammary glands [16–22]. 
The local RAS systems enable the generation of Ang 
II, and may therefore exert biological activity on an 
organ level. Recent studies suggest that, on a tissue 
level, the local RAS may influence cell proliferation 
and apoptosis, which are considered crucial in carci-
nogenesis [23, 24]. 
Evidence suggests that ACE may modify the ac-
tions of neuroendocrine peptides in the skin [25, 26]. 
It is noteworthy that proopiomelanocortin (POMC) 
— the neuroendocrine precursor protein — has 
also been found to be expressed in the innervating 
neurons, epidermal and dermal skin cells, and im-
mune cells, such as the Langerhans cells of the skin 
[25–27]. Some studies have suggested that one of the 
fragmentation products of POMC is adrenocortico-
tropin hormone (ACTH), which, together with its 
structurally related peptides (ACTH7-38, ACTH4-11, 
ACTH1-10 and ACTH18-39), has been shown to inhibit 
the activity of ACE in a noncompetitive way without 
being the substrate of the enzyme [28]. It has also 
been demonstrated that ACTH produced in the skin 
can be metabolized by ACE [27].
Nonmelanoma skin cancers (NMSC), including 
basal cell carcinoma (BCC) and squamous cell carci-
noma (SCC), are the most common skin cancers in the 
Caucasian population [29, 30]. SCC is less common 
than BCC, and accounts for 20% of all NMSC. It is 
related to a poorer prognosis due to the formation of 
metastases [31]. Actinic keratosis (AK) is regarded as 
the premalignant lesion of SCC that is induced mainly 
by exposure to UV radiation [32]. It is believed that 
AK transforms to carcinoma in situ, and subsequently 
to advanced SCC through a multistep cancerogenesis 
process [33].
Although ACE and ACE2 have been studied 
intensely in numerous human diseases, their expres-
sion in normal skin and its lesions has not yet been 
investigated. For this reason, the present study aimed 
to evaluate the immunoreactivity of ACE and ACE2 
in normal skin, AK, SCC, and BCC, with regard to 
patients’ clinical and pathological parameters.
Material and methods
Patients and tissue samples. The study was performed 
on archival paraffin blocks of 89 cases of skin lesions 
(16 cases of AK, 38 cases of SCC, and 35 cases of BCC) and 
14 cases of normal skin obtained from patients treated at 
the Department and Clinic of Dermatology, Venereology, 
and Allergology in Wroclaw during the years 2005–2007. 
In the BCC cases, 9 (25.7%) came from females and 
26 (74.3%) came from males. Twenty-three (65.7%) BCCs 
were from skin that was exposed to the sun, and the remaining 
12 (34.3%) were diagnosed in normally occulted body loca-
lizations (legs, trunk). The study included only superficial 
(15 cases; 42.9%) and nodular (57.1%) BCC subtypes. The 
clinical and pathological data of the SCC patients examined 
are summarized in Tables I and II.
Immunohistochemical (IHC) method. Tissue samples were 
fixed in 10% buffered formalin, dehydrated, and embedded 
in paraffin. Paraffin sections, 6 µm thick, were stained with 
haematoxylin and eosin (H&E) to verify the diagnosis. ACE, 
ACE2 and Ki-67 IHC staining was performed on 4-µm-thick 
paraffin sections fixed on Superfrost Plus slides (Menzel 
Gläser, Braunschweig, Germany). Deparaffinization and 
antigen retrieval were performed in Target Retrieval Solu-
tion with pH 9 (ACE, ACE2) or pH 6 (Ki-67) at 97°C for 
20 min using the PT Link platform (Dako, Glostrup, 
Denmark). Subsequently, the sections were washed in TBS 
(tris-buffered saline and incubated with primary antibodies 
directed against ACE (1:100, Santa Cruz Biotechnology, 
Santa Cruz, USA), ACE2 (1:100, Santa Cruz Biotechno-
logy), and Ki-67 (1:100, MIB-1, Dako) in an Autostainer 
Link48 automated staining platform (Dako) for 20 min at 
room temperature. The slides were then washed in TBS 
and visualization was performed using the EnVision FLEX 
system (Dako) according to the manufacturer’s instructions.
Histopathological examination and analysis of IHC reac-
tions. H&E sections were evaluated by two pathologists to 
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confirm the diagnosis and to assess the grade of tumor mali-
gnancy on Broders’ scale. The depth of skin infiltration was 
also established in the SCC cases. All IHC reactions were 
evaluated by two pathologists under BX-41 light microsco-
pe (Olympus, Tokyo, Japan). The evaluation of ACE and 
ACE2 reaction intensities was appraised using the 12-point 
immunoreactive (IRS) scale of Remmele and Stegner, in 
which the percentage of positive cells (0: absence of cells with 
positive reaction; 1 point: 1–10% cells; 2 points: 11–50%; 
3 points: 51–80%; 4 points: over 80% cells with positive 
reaction) and the intensity of the reaction (0: no reaction; 
1: low intensity of the reaction product; 2: moderate intensity 
of the reaction color; 3: intense color of the reaction) are 
taken into account. The final score assigned was the multi-
plicative product of these two parameters [34]. The immuno-
reactivity of Ki-67 was analyzed utilizing a semiquantitative 
5-point scale in which 0 denotes 0% positive nuclear stained 
cells, 1 represents 1–10%, 2 represents 11–25%, 3 represents 
26–50%, and 4 indicates > 50% [35]. In cases where the 
scores differed, the results were discussed by the observers 
until a consensus was achieved.
Statistical analysis. The obtained results were subjected to 
statistical analysis using Prism 5.0 software (GraphPad, CA, 
USA). The Mann-Whitney test was employed to compare 
ACE immunoreactivity in all the tested groups. Correlations 
between the analyzed markers were determined using the 
Spearman correlation test. Differences were considered 
significant when p < 0.05.
Results
ACE immunoreactivity was found in all cases of 
normal skin, AK, and SCC. Staining was observed 
in the cytoplasm and nuclei of cells of all epidermis 
layers, hair follicles, sebaceous glands, and cancer cells 
(Figure 1A–C, E). Similarly, almost all BCC cases 
(97.1%) were ACE-immunoreactive (Figure 1D). 
On the contrary, a weak ACE2 cytoplasmic reaction 
was seen only in the cells of the basal layer of the 
epidermis and sebaceous glands in normal skin, and 
not in AK or NMSC (Figure 1G–H). Nuclear Ki-67 
antigen immunoreactivity was observed in all the 
analyzed cases of normal skin and the studied skin 
lesions (Figure 1F).
The highest ACE immunoreactivity was noted in 
normal skin (IRS 9.07 ± 2.62). The intensity of the 
reaction was lower in cases of AK (IRS 6.75 ± 3.00) 
and BCC (IRS 6.31 ± 3.47), and was lowest in the 
SCC cases (IRS 4.13 ± 2.46) (Figure 2). The ACE 
immunoreactivity was significantly lower in SCC 
(p < 0.0001) and BCC (p < 0.01) when compared with 
normal skin. ACE immunoreactivity was also signifi-
cantly lower in the SCC cases, in comparison with AK 
(p < 0.01) and BCC (p < 0.05). It should be noted 
that an almost significant higher immunoreactivity of 
ACE was detected in normal skin, as compared with 
AK (p = 0.0516) (Figure 2).
No significant correlations were recorded between 
the immunoreactivity of ACE and Ki-67 antigen 
expression in all the studied cases and in particular 
lesions. No associations were noted between ACE 
immunoreactivity and the clinical or pathological data 
of the SCC and BCC patients. 
Table I. Patient and tumor character istics of the SCC 
cases
Parameter No. of cases (%)
Sex
   Male
   Female
22 (57.9)
16 (42.1)
Differentiation
   Keratodes
   Akeratodes
31 (81.6)
7 (18.4)
SCC on Broders’ scale
   1
   2
   3
   4
7 (18.4)
11 (28.9)
13 (34.3)
7 (18.4)
SCC depth of infiltration
   Epidermis
   Subcutaneous tissue
8 (21.0)
30 (89.0)
Density of inflammatory infiltration
   Mild
   Moderate
   Massive
8 (21.0)
22 (58.0)
8 (21.0)
Sun exposure
   Exposed
   Occulted
35 (92.1)
3 (7.9)
Table II. Patients’ age at diagnosis
Sex Mean age Min. Max. SD
All patients 68.40 12 97 14.52
Male 66.95 21 97 15.68
Female 69.42 12 89 13.69
SD — standard deviation
235ACE and ACE2 immunoreactivity in skin cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0033
www.fhc.viamedica.pl
Figure 1. Expression of ACE in: A. normal skin; B. actinic keratosis (AK); C. squamous cell carcinoma (SCC); D. basal 
cell carcinoma (BCC). E. A cytoplasmic-nuclear ACE immunoreactivity in normal skin keratinocytes. F. Nuclear Ki-67 
antigen immunoreactivity in BCC cancer cells. Arrows point ACE2 immunoreactivity in basal epidermis layer (G), and 
sebaceous gland (H)
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Discussion
In this immunohistochemical study, we documented 
a decrease in ACE immunoreactivity associated with 
the progression of carcinogenesis. The highest ACE 
immunoreactivity gradually decreased from high 
expression in normal skin along the carcinogenic 
pathway of SCC. 
Currently, there are no other reports showing 
the expression of RAS elements in normal skin or 
malignant skin lesions. In different organs, such as 
the pancreas, the local RAS system is autonomous 
from the activity of the systemic RAS and may exert 
differential biological effects, such as stimulation of 
angiogenesis, prevention of chemotherapy toxicity in 
pancreatic ductal adenocarcinoma, or initiation and 
propagation of acute pancreatitis [36]. Similarly to 
our own observations, Larrinaga et al. indicated the 
special role of intrarenal RAS (iRAS) in renal cancer. 
In this study, the activity and immunoreactivity of both 
ACE and ACE2 was downregulated in renal cancer 
cells, as compared with adjacent normal kidney tissue 
[37]. The authors speculated about the possibility of 
using these enzymes as prognostic and diagnostic fac-
tors, although this hypothesis remains to be clarified 
[37]. The role of RAS in cancer pathogenesis has also 
been supported by the study of Dolley-Hitze et al., 
which was performed on renal clear-cell cancer and 
recognized the expression of AT1R and AT2R as ne-
gative prognostic and predictive factors [38]. Thus, on 
the basis of our findings of the lower immunoreactivity 
of ACE in more malignant skin lesions as compared 
with the premalignant AK and normal skin, one could 
hypothesize a tumor-suppressing role of ACE. 
Many lines of evidence suggest that the use of ACE 
inhibitors (ACEi) and angiotensin receptor blockers 
(ARB) — both commonly used drugs in antihyper-
tensive therapy — might be preventative in cancer 
development through the inhibition of systemic and 
local RAS activity [39–44]. Patients with diagnosed 
urothelial tumor of the upper urinary tract treated 
with RAS inhibitors due to hypertension were cha-
racterized by longer event-free survival in comparison 
with patients treated with other antihypertensive 
drugs [39]. Similar observations were made by Su-
gimoto et al. for H. pylori related gastric cancer [40]. 
Several studies concerning the incidence of NMSC in 
patients treated with RAS inhibitors have confirmed 
the protective role of ACEi and angiotensin receptor 
blockers (ARBs) by showing the lower incidence of 
SCC and BCC in these patients’ cohorts, as compa-
red with patients treated with other antihypertensive 
drugs or without antihypertensive therapy [41–44].
In vitro investigations and studies on animal mo-
dels have confirmed the protective role of ACEi in 
tumor progression [45, 46]. Yoshiji et al. have shown 
that ACEi can suppress cell proliferation and vascu-
lar endothelial growth factor (VEGF) expression in 
hepatocellular carcinoma and angiogenesis [47]. In 
addition, in vitro investigations on triple negative bre-
ast cancer cell lines (lacking estrogen, progesterone, 
and HER2 receptors) and on invasive ductal breast 
carcinoma tissues have demonstrated the inductive 
role of ACE and AT1R in the process of breast cancer 
angiogenesis [48–50].
Although the population-based studies revealed 
that RAS inhibitors may be protective against NMSC 
[41, 42], in this study we found decreasing ACE 
expression with increasing malignant potential of the 
NMSC. Our results may indicate that ACE expression 
can act as a tumor suppressor and that the protective 
role of RAS inhibitors might be caused by the inhi-
bition of the systemic RAS and the generation of Ang-
(1-7) by ACE2 [15]. Higher levels of Ang-(1-7) could 
lead to increased apoptosis, decreased proliferation, 
and angiogenesis.
Moreover, local ACE expression via synthesis 
of Ang II could also downregulate the expression 
of Klotho protein, which has been shown to act as 
suppressor gene [51]. In a mouse model of glome-
rulonephritis, Klotho had a nephroprotective effect 
by abrogating oxidative stress [52]. In addition, mice 
characterized by overexpression of this protein show 
prolonged lifespan, in contrast to mice with knock-
down of its expression [51, 53]. Hypothetically, 
a decrease in ACE expression could result in Klotho 
overexpression in affected keratinocytes and in cancer 
cells increasing their survival capacities. However, this 
hypothesis requires further research.
Our research has shown that ACE2 immunoreac-
tivity is present only in the basal cell layer of normal 
Figure 2. Immunoreactivity of ACE as determined by 
Remmele and Stegner method [34] in normal skin, AK, 
SCC and BCC. *p < 0.05; **p < 0.01; ****p < 0.0001; 
Mann-Whitney test
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epidermis and sebaceous glands, and not in AK and 
NMSC. This may support the results of population 
studies regarding the administration of RAS inhibitors 
and the systemic role of Ang-(1-7) [13, 44].
This study failed to identify any associations with 
patients’ clinical and pathological data, since ACE 
immunoreactivity did not vary with patients’ age, 
lesion localization, invasive potential, extent of immu-
nological response, or cell proliferation measured by 
expression of the Ki-67 antigen. Similarly to Bieniek 
et al., we did not find any associations between Ki-67 
immunoreactivity and patients’ sex or BCC histolo-
gical subtype [54]. 
Our results of decreased expression of ACE in 
malignant skin cancers may indicate the involvement 
of ACE in the pathogenesis of SCC. ACE might also 
be involved in the pathogenesis of BCC, since its im-
munoexpression was significantly lower in this tumor 
in comparison with normal skin. Future studies are 
necessary to further elucidate the hypothetic tumor
-suppressing role of ACE. 
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